Keywords
neurosurgery
post-operational adjuvant therapy
chemotherapy
radiotherapy
How to Cite
Abstract
Active cohort randomized study including retro- and prospective, cross-sectional and dynamic components has been performed involving 176 patients with metastatic brain tumors (MBT). Peculiarities of post-operational period in patients with MBT after radiation therapy are quick early positive dynamics of neurologic symptoms, 47,4 % survival, 26,3 % relapses frequency, non-significant positive dynamics of quality of life mostly due to physical status. Peculiarities of post-operational period in patients with MBT after chemotherapy are late achievement of clinical effect and quality of life improvement (mostly due to social component), with resulting 12,9 % survival. Peculiarities of post-operational period in patients with MBT after consequent chemo- and radiation therapy are high parameters of neurological symptoms positive dynamics, survival, absence of tumors relapse.
References
Педаченко Є. Г. Концепція розвитку нейрохірургічної служби України / Є. Г. Педаченко, А. П. Гук // Укр. нейрохірург. журнал. – 2014. – № 2. – С. 4–7.
Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer / S. Ray, S. Dacosta-Byfield, A. Ganguli [et al.] // J. Neurooncol. – 2013. – V. 114, № 1. – P. 117–125.
Можаев С. В. Нейрохирургия / С. В. Можаев, А. А. Скоромец, Т. А. Скоромец. – М. : ГЭОТАР-Медиа, 2009. – 480 с.
Свинаренко А. В. Современные методы лечения метастазов в головной мозг / А. В. Свинаренко // Техногенна безпека. – 2012. – Т. 203, № 191. – С. 99–103.
Colaco R. Evolution of multidisciplinary brain metastasis management: case study and literature review / R. Colaco, P. Martin, V. Chiang // Yale J. Biol. Med. – 2015. – V. 88, № 2. – P. 157–165.
Зорін М. О. Лікування метастатичних пухлин головного мозку та прогнозування його результатів / М. О. Зорін, A. Г. Сірко // Укр. нейрохірург. журнал. – 2004. – № 2. – С. 10–18.
Colorectal carcinoma with hemiparesis due to isolated brain metastases as an initial symptom – a case report / A. Goto, Y. Ishimine, T. Hirata [et al.] // Gan To Kagaku Ryoho. – 2014. – V. 41, № 10. – P. 1245–1249.
Metastatic brain tumors from gastrointestinal cancer: an analysis of patient background and treatment results / Y. Mizokami, K. Mitsuya, N. Hayashi [et al.] // No Shinkei Geka. – 2013. – V. 41, № 8. – P. 669–677.
Променева терапія пухлин головного мозку / Д. А. Лазар, Д. С. Мечев, В. Д. Розуменко, Т. І. Чеботарева. – К. : Медицина України, 2010. – 170 с.
Рекомендации ESMO/ASCO по подготовке врачей-онкологов, специализирующихся в области лекарственного лечения злокачественных новообразований / [Ф. Андрэ, С. Берри, С. Бонвалот и др.]. – 2010. – 44 c.
Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO) / [под ред. В. М. Моисеенко]. – М. : Общество онкологов-химиотерапевтов, 2012. – 192 с.
ESMO Handbook of clinical pharmacology of anti-cancer agents / C. Sessa, L. Gianni, M. Garassino, H. van Halteren. – Viganello–Lugano : ESMO, 2012. – 288 p.
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine–DNA methyltransferase as a potential biomarker / M. C. Pietanza, K. Kadota, K. Huberman [et al.] // Clin. Cancer Res. – 2012. – V. 18, № 4. – P. 1138–1145.
Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases / R. Addeo, C. De Rosa, V. Faiola [et al.] // Cancer. – 2008. – V. 113, № 9. – P. 2524–2531.
Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial / C. Gamboa-Vignolle, T. Ferrari-Carballo, Ó. Arrieta, A. Mohar // Radiother. Oncol. – 2012. – V. 102, № 2. – P. 187–191.
Chemosensitized radiosurgery for recurrent brain metastases / D. Roberge, L. Souhami, M. A. Fortin, J. F. Pouliot // J. Neurooncol. – 2012. – V. 110, № 2. – P. 265–270.
Efficacy of procarbazine, lomustine, and vincristine chemotherapy for recurrent central nervous system lymphomas / Y. J. Kim, J. H. Choe, J. H. Park, Y. K. Hong // Brain Tumor Res Treat. – 2015. – V. 3, № 2. – P. 75–80.
Lassman A. B. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? / A. B. Lassman // CNS Oncol. – 2015. – V. 4, № 5. – P. 341–346.
Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space-occupying lesions / S. Van Meervenne, P. S. Verhoeven, J. de Vos [et al.] // Vet. Comp. Oncol. – 2014. – V. 12, № 1. – P. 67–77.